REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $533.61 million. The enterprise value is $534.86 million.
| Market Cap | 533.61M |
| Enterprise Value | 534.86M |
Important Dates
The last earnings date was Thursday, November 5, 2026, before market open.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 66.12 million shares outstanding. The number of shares has increased by 8.27% in one year.
| Current Share Class | 66.12M |
| Shares Outstanding | 66.12M |
| Shares Change (YoY) | +8.27% |
| Shares Change (QoQ) | +23.10% |
| Owned by Insiders (%) | 6.72% |
| Owned by Institutions (%) | 59.07% |
| Float | 57.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.47 |
| Forward PS | 5.16 |
| PB Ratio | 3.60 |
| P/TBV Ratio | 3.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.48 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.74, with a Debt / Equity ratio of 1.70.
| Current Ratio | 4.74 |
| Quick Ratio | 3.96 |
| Debt / Equity | 1.70 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.11 |
Financial Efficiency
Return on equity (ROE) is -113.24% and return on invested capital (ROIC) is -101.25%.
| Return on Equity (ROE) | -113.24% |
| Return on Assets (ROA) | -23.37% |
| Return on Invested Capital (ROIC) | -101.25% |
| Return on Capital Employed (ROCE) | -46.51% |
| Weighted Average Cost of Capital (WACC) | 11.12% |
| Revenue Per Employee | $414,854 |
| Profits Per Employee | -$472,315 |
| Employee Count | 371 |
| Asset Turnover | 0.31 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -28.01% in the last 52 weeks. The beta is 1.23, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.23 |
| 52-Week Price Change | -28.01% |
| 50-Day Moving Average | 7.77 |
| 200-Day Moving Average | 8.97 |
| Relative Strength Index (RSI) | 58.30 |
| Average Volume (20 Days) | 1,311,102 |
Short Selling Information
The latest short interest is 10.04 million, so 15.19% of the outstanding shares have been sold short.
| Short Interest | 10.04M |
| Short Previous Month | 9.61M |
| Short % of Shares Out | 15.19% |
| Short % of Float | 17.52% |
| Short Ratio (days to cover) | 6.44 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $153.91 million and -$175.23 million in losses. Loss per share was -$3.15.
| Revenue | 153.91M |
| Gross Profit | -99.32M |
| Operating Income | -185.30M |
| Pretax Income | -175.23M |
| Net Income | -175.23M |
| EBITDA | -170.30M |
| EBIT | -185.30M |
| Loss Per Share | -$3.15 |
Balance Sheet
The company has $250.98 million in cash and $252.22 million in debt, with a net cash position of -$1.25 million or -$0.02 per share.
| Cash & Cash Equivalents | 250.98M |
| Total Debt | 252.22M |
| Net Cash | -1.25M |
| Net Cash Per Share | -$0.02 |
| Equity (Book Value) | 148.04M |
| Book Value Per Share | 2.24 |
| Working Capital | 253.21M |
Cash Flow
In the last 12 months, operating cash flow was -$152.11 million and capital expenditures -$2.70 million, giving a free cash flow of -$154.80 million.
| Operating Cash Flow | -152.11M |
| Capital Expenditures | -2.70M |
| Depreciation & Amortization | 15.00M |
| Net Borrowing | n/a |
| Free Cash Flow | -154.80M |
| FCF Per Share | -$2.34 |
Margins
Gross margin is -64.53%, with operating and profit margins of -120.39% and -113.85%.
| Gross Margin | -64.53% |
| Operating Margin | -120.39% |
| Pretax Margin | -113.85% |
| Profit Margin | -113.85% |
| EBITDA Margin | -110.65% |
| EBIT Margin | -120.39% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -8.27% |
| Shareholder Yield | -8.27% |
| Earnings Yield | -39.05% |
| FCF Yield | -29.01% |
Analyst Forecast
The average price target for REGENXBIO is $24.00, which is 197.40% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $24.00 |
| Price Target Difference | 197.40% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 11 |
| Revenue Growth Forecast (3Y) | 27.33% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -2.99 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.99 |
| Piotroski F-Score | 3 |